SubHero Banner

Invokana® (canagliflozin), Invokamet® (canagliflozin/metformin) and Invokamet XR (canagliflozin/metformin extended-release) – Label updates

August 18, 2020 - The FDA approved updates to the drug labels for Invokana (canagliflozin), Invokamet (canagliflozin/metformin) and Invokamet XR (canagliflozin/metformin extended-release) regarding the removal of the boxed warning for lower limb amputation and the removal of the albuminuria condition for continued dosing of patients whose estimated glomerular filtration rate (eGFR) falls between 30 and less than 45 mL/min/1.73 m2.

Download PDF